Goldman Sachs
INDV icon

Goldman Sachs’s Indivior Pharmaceuticals INDV Stock Holding History

Goldman Sachs’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.4M Sell
2,409,165
-768,702
-24% -$25.4M 0.01% 1266
2025
Q4 		$114M Sell
3,177,867
-3,398,981
-52% -$104M 0.01% 913
2025
Q3 		$159M Sell
6,576,848
-2,987,243
-31% -$62.5M 0.02% 702
2025
Q2 		$141M Buy
9,564,091
+1,195,095
+14% +$13.9M 0.02% 717
2025
Q1 		$79.8M Buy
8,368,996
+1,299,425
+18% +$13.7M 0.01% 906
2024
Q4 		$87.9M Buy
7,069,571
+2,121,926
+43% +$21.8M 0.01% 885
2024
Q3 		$48.2M Buy
4,947,645
+3,551,179
+254% +$41.6M 0.01% 1275
2024
Q2 		$22.5M Sell
1,396,466
-3,263,921
-70% -$58.9M ﹤0.01% 1795
2024
Q1 		$99.8M Buy
4,660,387
+201,850
+5% +$3.79M 0.02% 784
2023
Q4 		$68.1M Sell
4,458,537
-1,224,501
-22% -$21.7M 0.01% 978
2023
Q3 		$131M Buy
5,683,038
+2,167,145
+62% +$49.4M 0.03% 593
2023
Q2 		$83.7M Buy
+3,515,893
New +$80.6M 0.02% 801

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs's INDV Position: Q1 2026 in Review

Goldman Sachs reduced its Indivior Pharmaceuticals (INDV) stake by 24% in Q1 2026, selling an estimated $25.4M and leaving 2,409,165 shares worth $73.4M. The position accounts for 0.01% of the portfolio, ranked #1266.

Goldman Sachs first reported a position in INDV in Q2 2023 and has held it in 12 quarters since. The position peaked at $159M in Q3 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Goldman Sachs held 2,409,165 shares of Indivior Pharmaceuticals worth $73.4M as of Q1 2026.
  • Goldman Sachs sold 768,702 Indivior Pharmaceuticals shares in Q1 2026, an estimated $25.4M.
  • Indivior Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1266 holding.
  • Goldman Sachs first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • Goldman Sachs's Indivior Pharmaceuticals position peaked at $159M in Q3 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.